Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   489 Trials   489 Trials   8953 News 


«12...6667686970717273747576...123124»
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer. (Pubmed Central) -  Jan 21, 2022   
    Lastly, knockdown of Nrf2 increased the sensitivity of anaplastic thyroid cancer cells to lenvatinib. As knockdown of Nrf2 reduced the metastatic and invasive ability of anaplastic thyroid cancer cells by inhibiting the Notch 1 signaling pathway and increased the cancer cell sensitivity to lenvatinib, Nrf2 could be a promising therapeutic target for patients with anaplastic thyroid cancer.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. (Pubmed Central) -  Jan 19, 2022   
    In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.
  • ||||||||||  lenvatinib / Generic mfg.
    Biomarker, Journal:  circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. (Pubmed Central) -  Jan 14, 2022   
    Our mechanistic investigations revealed that circMED27 functions as a competing endogenous RNA (ceRNA) for miR-655-3p to upregulate ubiquitin-specific peptidase 28 (USP28) expression. Thus, we are led to conclude that circMED27 acts as a potential therapeutic target for HCC patients receiving lenvatinib therapy and may represent a promising molecular biomarker for forecasting lenvatinib-resistant HCC.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, Trial completion date, Trial primary completion date:  TALENT: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (clinicaltrials.gov) -  Jan 10, 2022   
    P2,  N=80, Recruiting, 
    A larger-scale randomized clinical trial is needed. N=43 --> 80 | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. (Pubmed Central) -  Jan 7, 2022   
    Overall, the findings suggest that the underlying mechanism of lenvatinib in overcoming sorafenib resistance in HCC involves FGFR4-ERK signaling. Lenvatinib may be a suitable second-line therapy for unresectable HCC patients who have developed sorafenib resistance and express FGFR4.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) -  Jan 6, 2022   
    P2,  N=60, Active, not recruiting, 
    TACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma. Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Oct 2021 --> Oct 2022